Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 9

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 9
---
 effective as the combination therapy of phage and antibiotics in reducing P. aeruginosa CFUs in the lung. Additionally, approximately one-third of subjects treated with phage monotherapy exhibited at least
a 2-log CFU reduction in P. aeruginosa compared to no reduction in placebo treated subjects. Safety data indicate that
inhaled AP-PA02 was well-tolerated with treatment-emergent adverse events mild and self-limiting. There was one possibly related serious
adverse event that was linked to an acute pulmonary event requiring hospitalization that was responsive to antibiotics. We believe the
safety and tolerability of AP-PA02 offers a promising profile for treating chronically infected NCFB patients.

Results from the Phase 2
Tailwind study demonstrate the potential of Armata’s high-purity phage cocktail, AP-PA02, as a new monotherapy
treatment alternative for chronic pulmonary disease caused by P. aeruginosa infection, including drug-resistant
bacteria, and indicate the potential for phage therapy to reduce reliance on chronic antibiotic use. The Phase 2
Tailwind study represents the second successful clinical trial for AP-PA02, Armata’s lead pulmonary
candidate, which was first evaluated in people with cystic fibrosis in the Phase 1b/2a SWARM-P.a.trial that
completed in 2023. We believe the learnings on dose-schedule regimens gained from the two completed Phase 2 studies position us to
define a safe and promising biologic correlation for a Phase 3 definitive trial to evaluate inhaled AP-PA02 as an alternative to
antibiotics in chronic pulmonary P. aeruginosainfection.

Contingent upon securing
sufficient additional funding, we may at the appropriate time in the future resume clinical development of AP-PA02 for NCFB, which may
include the execution of a definitive Phase 3 clinical trial. We are also actively exploring potential strategic partnerships as a means
to further advance this important program.

<div align='center'>3</div>

Additional Clinical Indications for AP-PA02

The
current Pseudomonas phage cocktail formulated for inhalation (AP-PA02) is prepared with the same high potency and purity of our
injectable phage cocktail for Staphylococcus aureus (“S. aureus”) (AP-SA02). Based on the AP-SA02 clinical
findings, we are exploring the potential development of our Pseud